ALX Oncology
ALXO
89 hedge funds and large institutions have $2.78B invested in ALX Oncology in 2020 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 32 increasing their positions, 9 reducing their positions, and 8 closing their positions.
400% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 8
256% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 9
170% more capital invested
Capital invested by funds: $1.03B → $2.78B (+$1.75B)
56% more funds holding
Funds holding: 57 → 89 (+32)
36% more call options, than puts
Call options by funds: $551K | Put options by funds: $405K
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
8.07% more ownership
Funds ownership: 73.71% → 81.78% (+8.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$72.1M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$57.1M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$33.3M |
| 4 |
BlackRock
New York
|
+$32.7M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$25.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$11.3M |
| 2 |
VA
VR Adviser
New York
|
-$11.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.44M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$5.9M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.41M |
ALXO Hedge Fund Activity: Q4 2020 in Review
89 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q4 2020, worth a combined $2.78B — up 170% from $1.03B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new ALXO positions and 8 closed out — a net gain of 32 holders — while 32 added to existing stakes and 9 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $72.1M. The largest seller was Capital World Investors, exiting entirely with an estimated $11.3M sold.
- 89 institutional investors held ALX Oncology (ALXO) as of Q4 2020, up from 57 in Q3 2020.
- Funds reported $2.78B of ALX Oncology stock for Q4 2020, up 170% quarter-over-quarter.
- 40 funds opened new ALX Oncology positions in Q4 2020 and 8 closed out, a net change of +32 holders.
- The largest ALX Oncology buyer in Q4 2020 was Janus Henderson Group, an estimated $72.1M added.
- The largest ALX Oncology seller in Q4 2020 was Capital World Investors, an estimated $11.3M sold.
Based on aggregated 13F filings for Q4 2020.